December 16th, 2010 by Chris Hitchcock
There’s a new book about the intimate role of the pharmaceutical industry in the construction of diseases, using the example of FSD (female sexual dysfunction). The authors are Ray Moynihan, an Australian investigative journalist with a longstanding interest in this topic, and Barbara Mintzes, Assistant Professor in the Department of Pharmacology & Therapeutics at the University of British Columbia. I haven’t yet seen the book, but listened to the webinar, which is now available on the Canadian Women’s Health Network (CWHN) website.
There were a few things that struck me. One is how blatant the interference of the pharmaceutical industry can be. For example, the webinar includes a reference to an email sent to Lenore Tiefer letting her know that a formative 1997 meeting about female sexual dysfunction was only open to those who were either part of or willing to work with the pharmaceutical industry. Another was the way in which the language about the medical understanding of the cause of FSD tracked the introduction of 3 different potential drugs, each with different targets and different mechanisms. So far, each drug has failed in clinical trials.
The medicalization of human sexuality separates our bodies from our emotional lives, and creates a framework within which emotional or relationship difficulties are seen as being caused by the biological, rather than being interdependent. And little attention is paid to the ways in which pharmaceutical cures may even create relationship problems that were not there before.